Robyn R. Young

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Charles E. Geyer, William M. Sikov, Jens Huober et al. · Annals of Oncology · 2022 · 219 citations · Full text

Medicine, Oncology, Pharmacology +15

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Te-Chia Wu, Kangling Xu, Jan Martínek et al. · Cancer Research · 2018 · 161 citations · Full text

Medicine, Immunology, Oncology +17

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Denise A. Yardley, Rob Coleman, PierFranco Conte et al. · Annals of Oncology · 2018 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

Howard A. Burris, Fabienne Lebrun, Hope S. Rugo et al. · Cancer · 2013 · 100 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

Eric J. Small, Celestia S. Higano, N. Simon Tchekmedyian et al. · Journal of Clinical Oncology · 2006 · 69 citations

Medicine, Oncology, Pharmacology +17